Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4187/respcare.04797 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A comprehensive review of Langya virus and framework for future zoonotic disease control.
Rev Med Virol
January 2024
Online Research Club, Nagasaki, Japan.
First reported in August 2022, the Langya virus (LayV) has emerged as a potential global health threat in the post-COVID-19 era. Preliminary reports show that 35 patients near Shandong and Henan, China experienced a febrile acute LayV infection. We conducted this review following the PRISMA protocol to synthesise current knowledge on LayV's characteristics in terms of molecular, clinical, and public health perspectives.
View Article and Find Full Text PDFRespiratory syncytial virus: A new era.
Rev Esp Quimioter
April 2024
Servicio de Microbiología Clínica y Enfermedades Infecciosas del Hospital General Universitario Gregorio Marañón, Universidad Complutense. CIBERES. Ciber de Enfermedades Respiratorias. Madrid, Spain.
Article Synopsis
- Respiratory syncytial virus (RSV) has evolved from primarily affecting infants and immunosuppressed children to a common illness impacting all age groups, especially the elderly and those with immune issues.
- Advances in diagnostic testing have improved our understanding of RSV’s spread and effects, making it easier to identify.
- Recent developments in treatments, including long-lasting monoclonal antibodies and vaccines, have prompted a review of RSV by the ICOMEM to inform both medical professionals and the public about current knowledge and resources related to this infection in Spain.
Pretransplant ribavirin and interferon-α therapy for rhinovirus interstitial pneumonia in a RAG1-deficient infant.
J Infect Chemother
April 2024
Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Article Synopsis
- SCID is a serious genetic immune disorder that can lead to fatal infections, and the standard treatments include hematopoietic cell transplantation (HCT) and gene therapy.
- A case study highlights successful pretransplant treatment of severe pneumonia in a four-month-old with RAG1-deficiency, who responded well to ribavirin and interferon-α therapy.
- The patient's severe pneumonia due to rhinovirus and Pneumocystis jirovecii was managed effectively, enabling a curative HCT, and he is now a healthy three-year-old, demonstrating the importance of timely antiviral treatment in immunocompromised infants.
Best therapy for the easiest to treat hepatitis C virus genotype 1b-infected patients.
World J Gastroenterol
December 2022
Department of Infectious Diseases and Hepatology, Medical University of Białystok, Białystok 15-089, Poland.
Background: The revolution in treatment of patients with chronic hepatitis C virus (HCV) infection dates back to the introduction of direct-acting antivirals (DAAs). The increase in efficacy was most pronounced in patients infected with genotype (GT) 1b, as this was the most poorly responsive population to treatment during the interferon era.
Aim: To identify the most effective interferon-free therapy for GT1b-infected patients and to determine positive and negative predictors of virological response.
Efficacy and safety of direct-acting antiviral therapy for hepatitis C virus in elderly patients (≥65 years old): A systematic review and meta-analysis.
J Viral Hepat
July 2022
Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Korea.
Direct-acting agents (DAAs) have launched a new era of hepatitis C virus (HCV) treatment. As aged individuals comprise a large percentage of HCV-infected patients, the effectiveness and safety of DAAs in the elderly have come under scrutiny. This meta-analysis aimed to evaluate the efficacy and safety of DAAs in elderly patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!